XOMA reports Q3 2022 net loss $4.2M; receives first VABYSMO royalty from Roche

XOMA Royalty Corp

2022-Q3 EPS reported -$1.34 revenue$4,541,000

Total revenues $0.5M, down from $0.9M in Q3 2021; milestone revenue in prior year period.
Net loss $4.2M vs $4.4M year ago; cash $78.3M with no debt.
First commercial payment received from Roche for VABYSMO (faricimab) in wAMD and DME: $0.5M.
Received $2.5M milestone from Kuros after Regeneron's acquisition of Checkmate.
Paid $3.0M milestone to Affitech triggered by EU approval of VABYSMO.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

XOMA Royalty Corp reported the quarter ended September 30, 2022 results: revenue $0.5 million, net income $4.2 million.

Period: the quarter ended September 30, 2022
Revenue: $0.5 million
Net income: $4.2 million
Result: reported results

Exact text from the filing

XOMA recorded total revenues of $0.5 million for the third quarter of 2022

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

XOMA Royalty Corp filing history →

Source: SEC EDGAR

accession 0001193125-22-276404

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.